<DOC>
	<DOC>NCT01695434</DOC>
	<brief_summary>To explore whether treatment with glatiramer acetate (GA) may decrease iron deposition in subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months and compared to a reference population of healthy controls.</brief_summary>
	<brief_title>A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months</brief_title>
	<detailed_description>This is a prospective, observational, single-blinded, longitudinal, 24-month MRI study of the evolution of iron deposits, as evidenced by SWI-filtered phase imaging, in RRMS patients treated with GA and in healthy controls.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>MS patients diagnosed with clinically definite MS according to the McDonald criteria (Polman et al., 2005) Being on GA monotherapy (20mg/day sc) for at least 24 months prior to the 24month MRI scan Having baseline clinical MRI scan that included SWIfiltered phase imaging in a 12month window from the start day of the of the GA (MS patients) Having baseline clinical MRI scan that included SWIfiltered phase imaging (healthy controls) MS patients having a RR disease course (Lublin and Reingold, 1996) Age 1865 (healthy controls will be matched to MS patients for age and sex) Signed informed consent at the 24month followup Pass MRI health screening MS patients passing contrast screening MS patients having normal kidney function (creatinine clearance &gt;59) None of the exclusion criteria Patients who had a relapse within 30 days prior to MRI baseline scan date Patients who received steroid treatment within 30 days prior to the MRI baseline scan date Women who are pregnant, lactating or of childbearing age who do not consent to approved contraceptive use during the study MS patients who used other imunomodulatory or immunosuppressant treatment other than GA during the followup (e.g., IFNÎ², mitoxantrone, cyclophosphamide, cladribine, fludarabine, cyclosporine, total body, azathioprine, methotrexate, IVIG, cellcept, natalizumab, etc.) MS patients having abnormal kidney function (creatinine clearance &lt;59)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>MRI</keyword>
	<keyword>Copaxone</keyword>
	<keyword>healthy controls</keyword>
	<keyword>glatiramer acetate</keyword>
</DOC>